Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women

Clinical Infectious Diseases

Volumn 57, Issue 5, 2013, Pages 735-744

  Kahn, Jessica A ^a   Xu, Jiahong ^b   Kapogiannis, Bill G ^c   Rudy, Bret ^d   Gonin, René ^b   Liu, Nancy ^b   Wilson, Craig M ^e   Worrell, Carol ^c   Squires, Kathleen E ^f  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b WESTAT   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

HIV infected; human papillomavirus; immunogenicity; safety; vaccine

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ANTIVIRAL THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG SAFETY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOGENICITY; MAJOR CLINICAL STUDY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEROCONVERSION;

HIV INFECTED; HUMAN PAPILLOMAVIRUS; IMMUNOGENICITY; SAFETY; VACCINE;

ADOLESCENT; ANTIBODIES, VIRAL; FEMALE; HIV INFECTIONS; HUMAN PAPILLOMAVIRUS 11; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMAN PAPILLOMAVIRUS 6; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; YOUNG ADULT;

EID: 84881463065     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit319     Document Type: Conference Paper

References (34)

1. Ellerbrock TV, Chiasson MA, Bush TJ, et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 2000; 283:1031-7.
2. Hawes SE, Critchlow CW, Faye Niang MA, et al. Increased risk of highgrade cervical squamous intraepithelial lesions and invasive cervical cancer among African women with human immunodeficiency virus type 1 and 2 infections. J Infect Dis 2003; 188:555-63.
3. Guiguet M, Boue F, Cadranel J, Lang JM, Rosenthal E, Costagliola D. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): A prospective cohort study. Lancet Oncol 2009; 10:1152-9.
4. Abraham AG, Strickler HD, Jing Y, et al. Invasive cervical cancer risk among HIV-infected women: A North American multi-cohort collaboration prospective study. J Acquir Immune Defic Syndr 2013; 62:405-13.
5. Tanon A, Jaquet A, Ekouevi DK, et al. The spectrum of cancers inWest Africa: Associations with human immunodeficiency virus. PLoS One 2012; 7:e48108.
6. Massad LS, Fazzari MJ, Anastos K, et al. Outcomes after treatment of cervical intraepithelial neoplasia among women with HIV. J Low Genit Tract Dis 2007; 11:90-7.
7. Adam Y, van Gelderen CJ, de Bruyn G,McIntyre JA, Turton DA,Martinson NA. Predictors of persistent cytologic abnormalities after treatment of cervical intraepithelial neoplasia in Soweto, South Africa: A cohort study in a HIV high prevalence population. BMC Cancer 2008; 8:211.
8. Reimers LL, Sotardi S, Daniel D, et al. Outcomes after an excisional procedure for cervical intraepithelial neoplasia in HIV-infected women. Gynecol Oncol 2010; 119:92-7.
9. Centers for Disease Control and Prevention: FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010; 59:626-9.
10. Centers for Disease Control and Prevention: Recommendations on the use of quadrivalent human papillomavirus vaccine in males - Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011; 60:1705-8.
11. Bridges CB, Woods L, Coyne-Beasley T. Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for adults aged 19 years and older - United States, 2013. MMWR Surveill Summ 2013; 62(suppl 1):9-19.
12. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 viruslike particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95:1459-66.
13. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369:2161-70.
14. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356:1928-43.
15. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1915-27.
16. Koutsky LA. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1915-27.
17. Paavonen J. Efficacy of a quadrivalent HPV (types 6/11/16/18) L1 virus-like particle (VLP) vaccine against vaginal and vulvar pre-cancerous lesions: A combined analysis. J Clin Oncol 2006; 24:5011.
18. Neilsen GA, Bodsworth NJ, Watts N. Response to hepatitis A vaccination in human immunodeficiency virus-infected and -uninfected homosexual men. J Infect Dis 1997; 176:1064-7.
19. Amendola A, Tanzi E, Zappa A, et al. Safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-1 infected former drug users. Vaccine 2002; 20:3720-4.
20. Wallace MR, Brandt CJ, Earhart KC, et al. Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects. Clin Infect Dis 2004; 39:1207-13.
21. Obaro SK, Pugatch D, Luzuriaga K. Immunogenicity and efficacy of childhood vaccines in HIV-1-infected children. Lancet Infect Dis 2004; 4:510-8.
22. Bickel M, Wieters I, Khaykin P, et al. Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AIDS 2010; 24:F31-5.
23. Levin MJ, Moscicki AB, Song LY, et al. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr 2010; 55:197-204.
24. Opalka D, Lachman CE, MacMullen SA, et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 2003; 10:108-15.
25. Castle PE, Schiffman M, Gravitt PE, et al. Comparisons of HPV DNA detection by MY09/11 PCR methods. J Med Virol 2002; 68: 417-23.
26. Villa LL, Ault KA, Giuliano AR, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 2006; 24:5571-83.
27. Kahn JA, Xu J, Zimet GD, et al. Risk perceptions after human papillomavirus vaccination in HIV-infected adolescents and young adult women. J Adolesc Health 2012; 50:464-70.
28. Kahn JA, Burk RD, Squires KE, et al. Prevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination. J Acquir Immune Defic Syndr 2012; 61:390-9.
29. Fonseca MO, Pang LW, de Paula Cavalheiro N, Barone AA, Heloisa Lopes M. Randomized trial of recombinant hepatitis B vaccine in HIVinfected adult patients comparing a standard dose to a double dose. Vaccine 2005; 23:2902-8.
30. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6:271-8.
31. Olsson SE, Villa LL, Costa RL, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007; 25:4931-9.
32. O'Brien WA, Grovit-Ferbas K, Namazi A, et al. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 1995; 86: 1082-9.
33. Brichacek B, Swindells S, Janoff EN, Pirruccello S, Stevenson M. Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine. J Infect Dis 1996; 174:1191-9.
34. Staprans SI, Hamilton BL, Follansbee SE, et al. Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med 1995; 182:1727-37.